ClinicalTrials.gov record NCT02877706

French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Aug 22, 2026

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Age18 years old and older

SexAll

LocationFrance

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This is a prospective observational registry that records adult patients with newly diagnosed immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or adults starting FOSFAMATINIB. The study collects clinical features, treatments used, outcomes, and adverse events, and follows participants over the long term (up to 15 years).

What it is studying. The study aims to describe disease features and incidence, track natural history and events (bleeding, infection, thrombosis), record treatments and adverse reactions, and assess adherence to ITP/AIHA management guidelines.

What the researchers hope to learn. Describe clinical features and incidence of ITP and AIHA; document natural evolution and events; report response rates and complete rates; record lines of treatment and adverse drug reactions; measure bleeding, rescue treatments, adherence to management guidelines, and other events (cancer, death, infection, thrombosis) over 15 years.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other: no specific intervention

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

adult patients (18+ year-old)
newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB

Exclusion criteria

opposition to data collection

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants allow their clinical information to be entered into a registry at enrollment (baseline) and during follow-up visits. The study will record diagnosis details, treatments received, laboratory results and events of interest (for example bleeding, infections, thrombosis, and adverse drug reactions); the registry does not assign a study treatment. Follow-up and data collection can continue for up to 15 years according to the record.

How the study is structured. A prospective observational registry (cohort). There is no study-assigned treatment. Investigators record medical information at enrollment (baseline) and during follow-up visits for up to 15 years.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in France. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on autoimmune hemolytic anemia

Clinical trials49 trials listed for autoimmune hemolytic anemiaEvery trial the registry lists for autoimmune hemolytic anemia, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in autoimmune hemolytic anemia researchLatest monthly update: September 2026. Includes: Negative DAT cases. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: June 2013
Primary completion: December 2026 (estimated)
Study completion: December 2029 (estimated)
Target enrollment: 1500 participants (estimated)
Last updated on registry: Dec 31, 2025
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: University Hospital, Toulouse

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Moulis Guillaume, MD PhD ✉ moulis.g@chu-toulouse.fr
Johanne Germain, PhD ✉ johanne.germain@inserm.fr

Participating sites (1)

Service de Médecine InterneRecruiting
Toulouse, 31000 · France
- Moulis Guillaume, MD, PhD · moulis.g@chu-toulouse.fr

Terms used on this page · explanations by MedicalUpdates.ai

registry: An organised collection of information about people with a particular condition, gathered over time for research. Joining a registry usually means sharing medical information, not receiving a treatment.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials